288 related articles for article (PubMed ID: 31712729)
1. Proposal for a Quantitative
Takahashi MES; Mosci C; Souza EM; Brunetto SQ; Etchebehere E; Santos AO; Camacho MR; Miranda E; Lima MCL; Amorim BJ; de Souza C; Pericole FV; Lorand-Metze I; Ramos CD
Sci Rep; 2019 Nov; 9(1):16429. PubMed ID: 31712729
[TBL] [Abstract][Full Text] [Related]
2. Application of an artificial intelligence-based tool in [
Sachpekidis C; Enqvist O; Ulén J; Kopp-Schneider A; Pan L; Jauch A; Hajiyianni M; John L; Weinhold N; Sauer S; Goldschmidt H; Edenbrandt L; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3697-3708. PubMed ID: 37493665
[TBL] [Abstract][Full Text] [Related]
3. Computed tomography-based skeletal segmentation for quantitative PET metrics of bone involvement in multiple myeloma.
Takahashi MES; Mosci C; Souza EM; Brunetto SQ; de Souza C; Pericole FV; Lorand-Metze I; Ramos CD
Nucl Med Commun; 2020 Apr; 41(4):377-382. PubMed ID: 32058446
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow segmentation and radiomics analysis of [
Milara E; Gómez-Grande A; Tomás-Soler S; Seiffert AP; Alonso R; Gómez EJ; Martínez-López J; Sánchez-González P
Comput Methods Programs Biomed; 2022 Oct; 225():107083. PubMed ID: 36044803
[TBL] [Abstract][Full Text] [Related]
5. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
[TBL] [Abstract][Full Text] [Related]
6. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).
Nanni C; Zamagni E; Versari A; Chauvie S; Bianchi A; Rensi M; Bellò M; Rambaldi I; Gallamini A; Patriarca F; Gay F; Gamberi B; Cavo M; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):414-21. PubMed ID: 26475305
[TBL] [Abstract][Full Text] [Related]
7. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
Ak I; Gulbas Z
Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
[TBL] [Abstract][Full Text] [Related]
8. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
[TBL] [Abstract][Full Text] [Related]
9. PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics.
Sachpekidis C; Goldschmidt H; Hose D; Pan L; Cheng C; Kopka K; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1343-53. PubMed ID: 24562650
[TBL] [Abstract][Full Text] [Related]
10. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
Dammacco F; Rubini G; Ferrari C; Vacca A; Racanelli V
Clin Exp Med; 2015 Feb; 15(1):1-18. PubMed ID: 25218739
[TBL] [Abstract][Full Text] [Related]
11. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.
Fonti R; Larobina M; Del Vecchio S; De Luca S; Fabbricini R; Catalano L; Pane F; Salvatore M; Pace L
J Nucl Med; 2012 Dec; 53(12):1829-35. PubMed ID: 23071351
[TBL] [Abstract][Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
13. Treatment response evaluation with
Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
[TBL] [Abstract][Full Text] [Related]
14. The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma.
Sager S; Ergül N; Ciftci H; Cetin G; Güner SI; Cermik TF
Skeletal Radiol; 2011 Jul; 40(7):843-7. PubMed ID: 21229354
[TBL] [Abstract][Full Text] [Related]
15. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).
Nanni C; Versari A; Chauvie S; Bertone E; Bianchi A; Rensi M; Bellò M; Gallamini A; Patriarca F; Gay F; Gamberi B; Ghedini P; Cavo M; Fanti S; Zamagni E
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):712-719. PubMed ID: 29270787
[TBL] [Abstract][Full Text] [Related]
16. Different lesions revealed by 18F-FDG PET/CT and 18F-NaF PET/CT in patients with multiple myeloma.
Xu F; Liu F; Pastakia B
Clin Nucl Med; 2014 Sep; 39(9):e407-9. PubMed ID: 24217536
[TBL] [Abstract][Full Text] [Related]
17. Intensity of bone involvement: a quantitative 18F-FDG PET/CT evaluation for monitoring outcome of multiple myeloma.
Takahashi MES; Mosci C; Duarte GO; Pericole FV; Metze K; Lorand-Metze IGH; Ramos CD
Nucl Med Commun; 2021 Dec; 42(12):1375-1381. PubMed ID: 34347655
[TBL] [Abstract][Full Text] [Related]
18. Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI.
Zambello R; Crimì F; Lico A; Barilà G; Branca A; Guolo A; Varin C; Vezzaro R; Checuz L; Scapin V; Berno T; Pizzi M; Ponzoni A; De Biasi E; Vio S; Semenzato G; Zucchetta P; Lacognata C
Ann Hematol; 2019 Mar; 98(3):679-689. PubMed ID: 30539276
[TBL] [Abstract][Full Text] [Related]
19. Comparison of (11)C-4'-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma.
Okasaki M; Kubota K; Minamimoto R; Miyata Y; Morooka M; Ito K; Ishiwata K; Toyohara J; Inoue T; Hirai R; Hagiwara S; Miwa A
Ann Nucl Med; 2015 Apr; 29(3):224-32. PubMed ID: 25421383
[TBL] [Abstract][Full Text] [Related]
20. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
Mesguich C; Hulin C; Latrabe V; Lascaux A; Bordenave L; Hindié E; Marit G
Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
